Articles
Short notes on repeat FDA patterns.
Source-backed notes for readers who want the enforcement pattern before opening the source record.
FDA Warning Letters from August 2026: Five Records to Review
A source-linked review of five August 2026 FDA warning letters and the follow-up work compliance teams should track.
GLP-1 compounding after the shortage window
What FDA's GLP-1 compounding record tells compounders, clinics, supplier-quality teams, and compliance vendors to monitor next.
FDA tobacco warning-letter cluster
Why six same-day Center for Tobacco Products warning letters are a stronger compliance signal than another one-off recall.
Hidden drug ingredients in supplement recalls
Why undeclared sildenafil, tadalafil, and flibanserin remain a source-backed recall pattern for supplement sellers and marketplaces.
FDA's GLP-1 compounding crackdown
What FDA's public GLP-1 concerns mean for compounders, clinics, patients, and anyone tracking quality risk in the weight-loss drug supply chain.
OTC drug CGMP warning-letter patterns
Why manufacturing controls, lab controls, and quality-unit oversight keep showing up in recent public letters.
Device software and cyber recall signals
A practical way to read software maintenance releases and cyber vulnerability recall language.